Media 1: Monostatic coaxial 1.5 μm laser Doppler velocimeter using a scanning Fabry-Perot interferometer

Originally published in Optics Express on 09 September 2013 (oe-21-18-21105

Visualization 1: Eye-safe diode laser Doppler lidar with a MEMS beam-scanner

Video linked to Fig. 7. It is slowed down four times the original speed to show the dithered beam’s spiral trajectory. Originally published in Optics Express on 08 February 2016 (oe-24-3-1934

Names and synthesis conditions of drug containing geopolymer samples.

<p>Names and synthesis conditions of drug containing geopolymer samples.</p

N₂ isotherms for the geopolymer samples.

<p>N₂ isotherms for the geopolymer samples.</p

Release profiles in pH 6.8 and in 40 vol% ethanol.

<p>Comparison of release profiles for DR21-60 in pH 6.8 and in 40% ethanol, and for DR11-60 in pH 6.8 and pH 1.0 (pellet dimensions Ø: 1.5 mm · h: 1.5 mm).</p

XRD pattern for the geopolymer samples.

<p>The broad hump in the pattern is characteristic for amorphous geopolymer while the peak left to the bump is indicative for a formation of a crystalline phase.</p

Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy

Immunoglobulin A nephropathy (IgAN) is a chronic, immune-mediated kidney disease characterized by the deposition of galactose-deficient immunoglobulin A1 (Gd-IgA1) in the kidneys. Excess Gd-IgA1 production in patients with IgAN is located within the mucosa-associated lymphoid tissue, particularly within the lamina propria in the distal ileum. Nefecon® is a targeted-release formulation of the corticosteroid budesonide, which became the first treatment approved by the US Food and Drug Administration (FDA; brand name, TARPEYO®) and European Medicines Agency (EMA; KINPEYGO®) for patients with primary IgAN at risk of rapid disease progression, after demonstrating clinically significant reduction of proteinuria in an interim analysis of the Phase III NefIgArd trial. After showing a significant reduction in estimated glomerular filtration rate decline in the full 2-year analysis of the trial, Nefecon was granted full approval by the FDA to reduce the loss of kidney function. Nefecon was specifically designed to deliver budesonide to the distal ileum, selectively targeting excess Gd-IgA1 production in the gut-associated lymphoid tissue. In this review, we describe the properties of Nefecon and the evidence to date that confirms its localized treatment effect. We also present unpublished evidence from Phase I trials investigating the pharmacokinetics and cortisol suppression effects of Nefecon in healthy participants. These studies demonstrated that Nefecon has a distinct pharmacokinetic profile from other budesonide products, allowing for targeted, localized action in the distal ileum. When considered alongside existing clinical trial data showing the effect of Nefecon on gut-associated biomarkers, available evidence indicates that Nefecon has a selective immunomodulatory mechanism of action and a direct disease-modifying effect in patients with IgAN, while having low systemic exposure and adverse effects

Influence of pellet size on drug release profile.

<p>Oxycodone is released in pH 6.8, from DR11-RT pellets of two different dimensions: (i) Ø: 0.5 mm · h: 1.0 mm and (ii) Ø: 1.5 mm · h: 1.5 mm</p

Release profiles in pH 6.8 for the oxycodone carrying geopolymer samples.

<p>Each curve show the total release of oxycodone from roughly 135 pellets (weighing in total 600 mg) with the dimensions Ø: 1.5 mm · h: 1.5 mm.</p

Pore size distributions in the geopolymer samples.

<p>Pore size distributions in the geopolymer samples.</p